Home > Search Results: Wolinsky, Jerry S.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 3 records in 0.03 seconds.
Articles, 3 records found
Articles 3 records found  
1.
12 p, 888.5 KB Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis / Turner, Benjamin (The Royal London Hospital) ; Cree, Bruce A. C (University of California) ; Kappos, Ludwig (University Hospital Basel (Basilea, Suïssa)) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Papeix, Caroline (Pitié-Salpêtrière Hospital) ; Wolinsky, Jerry S. (The University of Texas Health Science Center at Houston (UTHealth)) ; Buffels, Regine (F. Hoffmann-La Roche Ltd) ; Fiore, Damian (Genentech. Inc) ; Garren, Hideki (Genentech. Inc) ; Han, Jian (Genentech. Inc) ; Hauser, Stephen L. (University of California) ; Universitat Autònoma de Barcelona. Departament de Medicina
Objective: The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported; here we present subgroup analyses of efficacy endpoints from the pooled OPERA I and OPERA II populations. [...]
2019 - 10.1007/s00415-019-09248-6
Journal of Neurology, Vol. 266 Núm. 5 (may 2019) , p. 1182-1193  
Detailed record - Creative Commons
2.
14 p, 1.2 MB Safety of Ocrelizumab in Patients with Relapsing and Primary Progressive Multiple Sclerosis / Hauser, Stephen L. (University of California) ; Kappos, Ludwig (University of Basel) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Craveiro, Licinio (F. Hoffmann-La Roche Ltd.) ; Chognot, Cathy (F. Hoffmann-La Roche Ltd.) ; Hughes, Richard (F. Hoffmann-La Roche Ltd.) ; Koendgen, Harold (F. Hoffmann-La Roche Ltd.) ; Pasquarelli, Noemi (F. Hoffmann-La Roche Ltd.) ; Pradhan, Ashish (Genentech Inc.) ; Prajapati, Kalpesh (IQVIA Solutions Inc.) ; Wolinsky, Jerry S. (Health Science Center at Houston) ; Universitat Autònoma de Barcelona
Background and Objectives To report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings. [...]
2021 - 10.1212/WNL.0000000000012700
Neurology, Vol. 97 Núm. 16 (october 2021) , p. E1546-E1559  
Detailed record - Creative Commons
3.
9 p, 341.7 KB Risk of requiring a wheelchair in primary progressive multiple sclerosis : Data from the ORATORIO trial and the MSBase registry / Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Butzkueven, Helmut (Monash University) ; Spelman, Tim (University of Melbourne) ; Horakova, Dana (Charles University. Faculty of Medicine in Hradec Králové) ; Hughes, Stella (Craigavon Area Hospital) ; Solaro, Claudio Marcello (CRRF "Mons. Luigi Novarese") ; Izquierdo, Guillermo (Hospital Vithas Nisa) ; Kubala Havrdova, Eva (Charles University) ; Grand'Maison, Francois (Neuro Rive-Sud) ; Prat, Alexandre (Universite de Montreal) ; Girard, Marc (Universite de Montreal) ; Hupperts, Raymond (Zuyderland Ziekenhuis) ; Onofrj, Marco (University G. d'Annunzio) ; Lugaresi, Alessandra (UOSI Riabilitazione Sclerosi Multipla) ; Taylor, Bruce (Royal Hobart Hospital) ; Giovannoni, Gavin (Queen Mary University of London) ; Kappos, Ludwig (University of Basel) ; Hauser, Stephen L. (University of California) ; Craveiro, Licinio (F. Hoffmann-La Roche Ltd) ; Freitas, Rita (F. Hoffmann-La Roche Ltd) ; Model, Fabian (F. Hoffmann-La Roche Ltd) ; Overell, James (F. Hoffmann-La Roche Ltd) ; Muros-Le Rouzic, Erwan (F. Hoffmann-La Roche Ltd) ; Sauter, Annette (F. Hoffmann-La Roche Ltd) ; Wang, Qing (F. Hoffmann-La Roche Ltd) ; Wormser, David (F. Hoffmann-La Roche Ltd) ; Wolinsky, Jerry S. (McGovern Medical School) ; MSBase Study Group ; Universitat Autònoma de Barcelona
Background and purpose: Reaching Expanded Disability Status Scale (EDSS) ≥7. 0 represents the requirement for a wheelchair. Here we (i) assess the effect of ocrelizumab on time to EDSS ≥7. 0 over the ORATORIO (NCT01194570) double-blind and extended controlled periods (DBP+ECP), (ii) quantify likely long-term benefits by extrapolating results, and (iii) assess the plausibility of extrapolations using an independent real-world cohort (MSBase registry; ACTRN12605000455662). [...]
2022 - 10.1111/ene.14824
European Journal of Neurology, Vol. 29 Núm. 4 (2022) , p. 1082-1090  
Detailed record - Creative Commons

See also: similar author names
1 Wolinsky, Jerry
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with